Dispositifs de délivrance de principes actifs pour des applications ophtalmologiques

Bourges, Jean‐Louis; Touchard, Elodie; Kowalczuk, Laura; Berdugo, Marianne; Thomas-Doyle, A.; Bochot, Amélie; Gómez, Ana M.; Azan, F.; Gurny, Robert

doi:10.1016/s0181-5512(07)79290-2

Cited by 7 publications

(2 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After local injection administration, sustained-release preparations can directly release drug at the therapeutic position and slowly enter into the bloodstream, thereby extending treatment time, enhancing treatment effects, and reducing systemic toxicity. Thus, this technology has the potential to reduce administration time, increase patient medication adherence and reduce therapeutic expenses 28,29. Several injectable sustained-release preparations have been developed, including for analgesic and endomyocardial applications, the steroid amcinonide, polypeptides, vaccines and gene-targeting drugs 30,31…”

Section: Discussionmentioning

confidence: 99%

Protection Provided by a Gabexate Mesylate Thermo-SensitiveIn SituGel for Rats with Grade III Pancreatic Trauma

Gao

Song

et al. 2017

Gut and Liver

View full text Add to dashboard Cite

Background/AimsThis study investigated the protection provided by gabexate mesylate thermo-sensitive in-situ gel (GMTI) against grade III pancreatic trauma in rats.MethodsA grade III pancreatic trauma model with main pancreatic duct dividing was established, and the pancreas anatomical diagram, ascites, and serum biochemical indices, including amylase, lipase, C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α), were examined. The pancreas was sliced and stained with hematoxylin eosin and subjected to terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining.ResultsAscites, serum amylase, lipase, CRP, IL-6, and TNF-α levels were significantly increased in the pancreas trauma (PT) groups with prolonged trauma time and were significantly decreased after GMTI treatment. The morphological structure of the pancreas was loose, the acinus was significantly damaged, the nuclei were irregular and hyperchromatic, and there was inflammatory cell invasion in the PT group compared to the control. After GMTI treatment, the morphological structure of the pancreas was restored, and the damaged acinus and inflammatory cell invasion were decreased compared to the PT group. Moreover, the cell apoptosis index was significantly increased in the PT group and restored to the same levels as the control group after GMTI treatment.ConclusionsGMTI, a novel formulation and drug delivery method, exhibited specific effective protection against PT with acute pancreatitis therapy and has potential value as a minimally invasive adjuvant therapy for PT with acute pancreatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Protection Provided by a Gabexate Mesylate Thermo-SensitiveIn SituGel for Rats with Grade III Pancreatic Trauma

Gao

Song

et al. 2017

Gut and Liver

View full text Add to dashboard Cite

show abstract

“…In addition, the liposomal membrane is flexible and supports deformation stress. The property makes them suitable for administering intraocular injections for treating posterior segment ocular diseases [45]. Positively charged liposomes disintegrate completely upon contact with negatively charged mucin membrane [46].…”

Section: Ophthalmic Nanoformulationsmentioning

confidence: 99%

Recent Patents on Ophthalmic Nanoformulations and Therapeutic Implications

Ako-Adounvo¹,

Nagarwal²,

Oliveira³

et al. 2014

DDF

View full text Add to dashboard Cite

Nanoformulations (NF) are widely explored as potential alternatives for traditional ophthalmic formulation approaches. The effective treatment of ocular diseases using conventional eye drops is often hampered by factors such as: physiological barriers, rapid elimination, protein binding, and enzymatic drug degradation. Combined, these factors are known to contribute to reduced ocular residence time and poor bioavailability. Recent research studies demonstrated that NF can significantly enhance the therapeutic efficacy and bioavailability of ocular drugs, compared to the established ophthalmic drug delivery strategies. The research studies resulted in a number of patent inventions, reporting a significant increase in therapeutic efficacy for various chronic ocular disease states of both the anterior and posterior ocular segments. This article reviews these patent disclosures in detail and emphasizes the therapeutic advantages conferred by the following nanoformulation approaches: Calcium Phosphate (CaP) nanoparticles, Liposomes, Nanoemulsions, Nanomicelles, and Hydrogels. The nanoformulation approaches were shown to enhance the ocular bioavailability by reducing the drugprotein binding, increasing the corneal resident time, enhancing the drug permeability and providing a sustained drug release. Further, the article discusses United States Food and Drug Administration (USFDA) approved ocular drugs employing nanotechnology and future developments. It should be noted that, despite the potential therapeutic promise demonstrated by nanotechnology for ocular drug delivery, the bench to bed transition from patent inventions to marketed drug products has been insignificant. Majority of the discussed technologies are still in development and testing phase for commercial viability. Further, studies are in progress to assess ocular tolerance and nanotoxicity for prolonged use of NF.

show abstract

The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins

Touchard

Kowalczuk

Bloquel

et al. 2010

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

Dispositifs de délivrance de principes actifs pour des applications ophtalmologiques

Cited by 7 publications

References 113 publications

Protection Provided by a Gabexate Mesylate Thermo-SensitiveIn SituGel for Rats with Grade III Pancreatic Trauma

Protection Provided by a Gabexate Mesylate Thermo-SensitiveIn SituGel for Rats with Grade III Pancreatic Trauma

Recent Patents on Ophthalmic Nanoformulations and Therapeutic Implications

The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins

Contact Info

Product

Resources

About